LS CancerDiag Ltd.

Based in Finland, LS CancerDiag Ltd. specializes in developing advanced diagnostic solutions for hereditary cancers, focusing on Lynch syndrome detection through innovative testing methods. LS CancerDiag Ltd. was founded in 2013 in Helsinki, Finland, where it focuses on diagnostic solutions for cancer predisposition disorders.

The company has completed a total of 2 deals and recently raised EUR 5. 4 million in a funding round on March 13, 2023, from investor Springvest Oy. Hannes Lohi is the founder of the company, while Niklas Lahti serves as CEO. The latest funding round brings the total amount raised to EUR 5.

4 million. LS CancerDiag Ltd. offers advanced diagnostic solutions for Lynch syndrome, primarily through its DiagMMR test, which detects mismatch repair (MMR) deficiencies. This diagnostic service is critical as only 35% of Lynch syndrome cases are confirmed with traditional DNA sequencing.

The primary clientele includes healthcare providers and families affected by hereditary cancers, with a focus on markets in North America and Europe. LS CancerDiag Ltd. operates a revenue model based on B2B transactions with healthcare providers for its DiagMMR test. In 2023, the company reported a revenue of EUR 0, with an EBITDA of EUR -1,477,094.

2, driven by direct partnerships with medical facilities for testing. Following the capital raise of EUR 5. 4 million on March 13, 2023, LS CancerDiag Ltd. aims to enhance its technological capabilities.

The funds will primarily support the development of new technology aimed at improving diagnostic services. The company plans to expand its market reach, although specific geographic targets have not been detailed.